Bio-Protocol (May 2021)

In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining

  • Miguel Hueso,
  • Adrian Mallen,
  • Elia Ripoll,
  • Laura de Ramon,
  • Nuria Bolaños,
  • Christian Valera,
  • Jordi Guiteras,
  • Javier Raya,
  • Estanislao Navarro,
  • Josep Maria Grinyo,
  • Josep Maria Cruzado,
  • Josep Maria Aran,
  • JUAN TORRAS

DOI
https://doi.org/10.21769/BioProtoc.4032
Journal volume & issue
Vol. 11, no. 10

Abstract

Read online

The co-stimulatory molecule CD40 and its ligand CD40L play a key role in the regulation of immunological processes and are involved in the pathophysiology of autoimmune and inflammatory diseases. Inhibition of the CD40-CD40L axis is a promising therapy, and a number of strategies and techniques have been designed to hinder its functionality. Our group has broad experience in silencing CD40 using RNAi technology, and here we summarize protocols for the systemic administration of a specific anti-CD40 siRNA in different rodents models, in addition to the subsequent quantification of CD40 expression in murine kidneys by immunostaining. The use of RNAi technology with specific siRNAs to silence genes is becoming an essential method to investigate gene functions and is rapidly emerging as a therapeutic tool.Graphic abstract:CD40 siRNA mechanism